Abstract:The connection of two or more proteins with different binding specificities or activities can lead to unique and powerful systems with significant potential in therapeutic applications, particularly oncology. While a plethora of active bifunctional proteins have been produced by fusion, this approach is not always viable, since modification of the N- or C- terminus can compromise the proteins’ bioactivities, with complications during folding and processing often being observed. Chemical cross-linking can offer a more versatile strategy towards the synthesis of protein-protein conjugates. However, current state-of-the-art approaches are either not selective, yielding heterogeneous mixtures or require mutations with natural or unnatural amino acids, which are often associated with low expression yields and limited applicability towards all protein systems. Recently, a bis-dibromomaleimide cross-linking reagent was used to create a bispecific scFv-Fab antibody in a site-specific manner, by targeting and bridging disulfide bonds. In this work, the application of these cross-linking reagents was extended into the conjugation of proteins containing different reactive handles, as well as sterically hindered conjugation sites. Diiodo-maleimides were shown to offer the ideal properties of rapid bioconjugation and importantly, reduced hydrolysis, which was identified as a significant factor affecting the conjugation efficiency. The optimized linkers were exploited to link human serum albumin to antibody fragments (scFv and Fab) as a prospective half-life extension platform, with retention of antigen binding and robust serum stability. The linker design was also extended to incorporate a third point of attachment for another biomolecule. An anti-CEA scFv homotrimer was formed, by disulfide bridging, which was shown to infer a combination of greater antigen avidity and increased in vivo half-life. Finally, with the view to developing a Bispecific T-cell Engager (BiTE) construct that could lead to more efficient cell-killing, an anti-CEA/ anti-CD3 scFv heterotrimer of increased avidity towards CD3 antigen was developed, showing the potential of this strategy for the construction of a diverse range of bioconjugates. The last part of this thesis describes investigations towards the development of a new methodology that selectively modifies specific lysine residues, via acyl transfer from the disulfide bond of Fab antibody fragment. This approach is expected to complement disulfide bridging as a strategy for selective modification, but also be advantageous for systems where this could result in detrimental changes to the antibody structure, offering a highly promising platform for bioconjugation.

A novel concept for cleavable linkers applicable to conjugation chemistry – design, synthesis and characterization

Recent Advances in the Linkers of Drug Conjugates

Thiol-Specific Linkers for the Synthesis of Oligonucleotide Conjugates via Metal-Free Thiol-Ene Click Reaction

The Chan-Lam-type synthesis of thioimidazolium salts for thiol-(hetero)arene conjugation

Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate

Disulfide-Based Self-Immolative Linkers and Functional Bioconjugates for Biological Applications

Use of a Cyclic α-Alkylidene-β-Diketone as a Cleavable Linker Strategy for Antibody-Drug Conjugates

Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody-Drug Conjugates

A light-responsive, self-immolative linker for controlled drug delivery via peptide- and protein-drug conjugates.

Modular and Automated Synthesis of Oligonucleotide-Small Molecule Conjugates for Cathepsin B Mediated Traceless Release of Payloads

Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates

A One-Pot Photocatalytic Triazole-Based Linkerology for PROTACs

Linkers in fragment-based drug design: an overview of the literature

Optimizing Lysosomal Activation of Antibody-Drug Conjugates (ADCs) by Incorporation of Novel Cleavable Dipeptide Linkers

Emerging Applications of Fluorogenic and Non-Fluorogenic Bifunctional Linkers.

New Strategies for Cysteine Bioconjugation and Protein Cross-Linking

Conjugation of Small Molecules to RNA Using a Reducible Disulfide Linker Attached at the 2′-OH Position through a Carbamate Function

Frontispiece: Emerging Applications of Fluorogenic and Non‐fluorogenic Bifunctional Linkers

Azobenzene‐based Linker Strategy for Selective Activation of Antibody‐Drug Conjugates

Engineered cysteine antibodies: an improved antibody-drug conjugate platform with a novel mechanism of drug-linker stability

Preparation of a Convertible Spacer Containing a Disulfide Group for Versatile Functionalization of Oligonucleotides